Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by Deutsche Bank AG

Deutsche Bank AG lifted its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 28.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 85,949 shares of the company's stock after purchasing an additional 18,939 shares during the quarter. Deutsche Bank AG owned about 0.15% of Harmony Biosciences worth $2,958,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of HRMY. D. E. Shaw & Co. Inc. raised its position in Harmony Biosciences by 35.0% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 480,605 shares of the company's stock valued at $16,538,000 after acquiring an additional 124,656 shares in the last quarter. Deep Track Capital LP purchased a new position in Harmony Biosciences during the fourth quarter valued at approximately $49,894,000. Cresset Asset Management LLC grew its holdings in Harmony Biosciences by 11.8% in the fourth quarter. Cresset Asset Management LLC now owns 71,765 shares of the company's stock valued at $2,469,000 after purchasing an additional 7,557 shares during the period. BOKF NA grew its holdings in Harmony Biosciences by 4.7% in the fourth quarter. BOKF NA now owns 15,400 shares of the company's stock valued at $521,000 after purchasing an additional 690 shares during the period. Finally, Brevan Howard Capital Management LP acquired a new stake in Harmony Biosciences in the fourth quarter valued at approximately $1,491,000. 86.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

HRMY has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft initiated coverage on Harmony Biosciences in a report on Tuesday, February 11th. They issued a "buy" rating and a $55.00 price objective on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $49.00 price target on shares of Harmony Biosciences in a research note on Tuesday, May 6th. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 price target on shares of Harmony Biosciences in a research note on Tuesday, April 8th. Cantor Fitzgerald raised Harmony Biosciences to a "strong-buy" rating in a research note on Tuesday, May 13th. Finally, UBS Group lowered their price target on Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Monday, April 28th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Harmony Biosciences presently has an average rating of "Buy" and a consensus target price of $52.78.

Harmony Biosciences Stock Up 0.1%

HRMY traded up $0.04 on Friday, hitting $34.17. 392,819 shares of the company were exchanged, compared to its average volume of 602,079. Harmony Biosciences Holdings, Inc. has a twelve month low of $26.47 and a twelve month high of $41.61. The company has a market cap of $1.96 billion, a price-to-earnings ratio of 16.19, a price-to-earnings-growth ratio of 0.47 and a beta of 0.82. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The firm has a 50-day moving average price of $31.58 and a two-hundred day moving average price of $34.02.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.59 by $0.19. The firm had revenue of $184.73 million during the quarter, compared to analysts' expectations of $184.26 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. Harmony Biosciences's revenue for the quarter was up 19.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.67 EPS. On average, equities analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.